Led by Nigel Keen, our Chair, the MedAccess board is responsible for our oversight and governance. Board members are drawn from the fields of public health, pharmaceuticals and finance.
Nigel brings decades of experience in healthcare and commerce to the oversight and governance of MedAccess. His career has encompassed venture capital, industry and banking, and he has been involved in the formation and development of high technology businesses for more than 30 years.
He is currently Chairman of Syncona Investment Management, Oxford Academic Health Science Network and Oxford University Innovation. He also Chairs the AIM-listed medical device company Deltex Medical Group.
Daniel brings 25 years’ experience in international finance to his position as a MedAccess director. During 11 years with the pharmaceutical group Aventis, he held a number of Chief Financial Officer roles, followed by 10 years as CFO at energy firm EDF. Daniel most recently served as CFO of the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Daniel holds several other Non-Executive Director positions including with the Foundation for Innovative New Diagnostics (FIND), a Swiss-based non-profit healthcare organisation.
Diana brings over 30 years’ experience in private equity, venture capital and international development. She combines Board responsibilities with chairing the MedAccess Investment Committee.
Diana has held roles of CEO at CDC Group, Executive Vice President Operations at the Clinton Health Access Initiative and Partner at Schroder Ventures (now Permira).
Egbe is a Partner at the Anadach Group, providing advisory services to a wide range of clients. She is a member of the UK Royal College of Physicians, with over 30 years’ healthcare experience covering policy, provision and financing in Africa, Asia, Europe, and Latin America.
Egbe has held various positions at the World Bank Group, working on public policy and investment transactions at the International Financial Corporation.
Holger is Managing Director of the Debt team at CDC Group. He has spent over 20 years in development finance in Latin America, Africa, Asia and Eastern Europe, working across numerous emerging markets, sectors and products.
Prior to joining CDC, Holger held several senior positions at the German Development Finance Institution, including building the Equity & Mezzanine Team. He started his career as a commercial banker with Deutsche Bank.
Willem is a former Senior Vice President at Roche Pharma in Switzerland.
He has over 34 years of experience in the pharmaceutical industry, culminating in various global leadership roles in product development, business development, strategic marketing, R&D strategy and portfolio management. His broad and deep experience covers a wide range of therapeutic areas and geographies.
The Board delegates specific tasks and decisions to three standing committees, which have Committee Chairs that report on their activities to the Board: